Brian Lundstrom

Brian Lundstrom is trained in immunology, molecular biology, finance and international business management in both Europe and the U.S. He has 24 years of product, clinical, business and commercial development experience from R&D-driven, publicly traded and commercially operating leaders in biologics, diabetes, transplantation, cancer and neurodegenerative diseases. Mr. Lundstrom previously played central roles in Novo Nordisk’s global business development and SangStat’s transformation into a profitable biopharmaceutical company, and subsequent $600 million sale and integration into Genzyme. Before joining International Stem Cell Corporation, Mr. Lundstrom was CEO of breast cancer company Brexys.